SecBot SecBot
SECBOTREPLAY Home › Report › PVLA

PVLA · Palvella Therapeutics reported Q2 2026 results with a net loss of $1.52…

PALVELLA THERAPEUTICS, INC. · 8-K filed Aug 4, 2026 at 07:30 ET

At the news

NEUTRALIMPACT 5/10

8-K filed Aug 4, 2026 at 07:30 ET

Palvella Therapeutics reported Q2 2026 results with a net loss of $1.52 per share, missing the consensus estimate of $-1.15 by 32%. The company is a pre-revenue clinical-stage biotech, so the EPS miss is a mechanical artifact of increased R&D spending and share dilution from the February 2026 equity raise, not a business deterioration signal. The key catalyst is the ongoing rolling NDA submission for QTORIN rapamycin in microcystic lymphatic malformations, which remains on track for completion in H2 2026, with a potential U.S. launch in H1 2027. The company has a strong cash position of $250.6M, funding operations and launch preparations through 2027.

  • Net loss of $21.9M ($1.52/share) for Q2 2026, compared to net loss of $9.5M ($0.86/share) in Q2 2025.
  • EPS of $-1.52 missed the consensus estimate of $-1.15 by 32%.
  • Cash, cash equivalents, and short-term investments were $250.6M as of June 30, 2026.
  • First module of the rolling NDA for QTORIN rapamycin in microcystic lymphatic malformations submitted to FDA; completion on track for H2 2026.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access